Thrombolex Inc.

Call Directions Website Contact the practice

THROMBOLEX® innovates mechanically channeled thrombolysis, disrupting and dissolving pulmonary embolism thrombus in a single on-the-table session.

10/29/2026

What happens once the channel opens?

Once the basket fissures the thrombus and the lytic goes to work, benefit doesn't stop at the main pulmonary artery. Segmental artery occlusions were reduced 71% at 48 hours* — and segmental clearance was the only level that correlated with right-heart recovery, not the main-artery reduction.

Watch the mechanism of action here: https://vimeo.com/1240906504?share=copy&fl=sv&fe=ci

*Citation on file with THROMBOLEX.

10/28/2026

THROMBOLEX® is excited to announce new interim results from the RAPID-PE study.

In this interim analysis of 150 of 350 planned patients, the THROMBOLEX device achieved 100% procedural success, with no device-related major adverse events and no intracranial hemorrhages.*

Learn more about the study at thrombolex.com.

*Data on file with THROMBOLEX.

10/27/2026

Why does distal clot matter just as much as central clot?

In this 60-second clip, Dr. Bertolet breaks down why treating thrombus in the distal segmental branches, not just the main pulmonary artery, plays such a big role in right-heart recovery.
The reduction in segmental occlusion correlated with right ventricle-to-left ventricle (RV/LV) recovery.* Learn more about how THROMBOLEX® can help your patients recover without requiring ICU stay at thrombolex.com.

Learn more at thrombolex.com

*Citation on file with THROMBOLEX.

10/22/2026

In the RESCUE pivotal Investigational Device Exemption (IDE) trial, the THROMBOLEX® procedure was associated with a 33.3% mean reduction in right ventricle-to-left ventricle (RV/LV) ratio at 48 hours, a core-lab-assessed measure of right-heart recovery.

Reduction in segmental artery occlusion was the only level that correlated with that recovery. Access recovery for your patients with THROMBOLEX for Mechanically Channeled Thrombolysis.*

Learn more at thrombolex.com

*Citation on file with THROMBOLEX.

10/20/2026

The THROMBOLEX® Mechanism of Action differentiates it: mechanical channeling paired with targeted lytic delivery in a single session — that's Mechanically Channeled Thrombolysis.

RESCUE, the pivotal trial, evaluated that mechanism using an infusion-based protocol, with core-lab imaging showing reduced thrombus burden in both the main pulmonary arteries and the smaller segmental branches, along with right-heart recovery.*

RESCUE-II feasibility study tested the same mechanism delivered as a single on-the-table session, with imaging showing a similar pattern of reduced thrombus burden in proximal and segmental arteries.*

RAPID-PE, a larger multicenter study now enrolling, has reported interim procedural safety and success data for that mechanism across a broader group of operators and patients.*

Swipe through for a look at the refreshed mark.

Learn more at thrombolex.com

*Citation on file with THROMBOLEX.

10/15/2026

A single on-the-table session. No infusion left running afterward. That’s what the RESCUE-II feasibility study demonstrated.

The THROMBOLEX® procedure delivered 8 mg (bilateral) r-tPA in one session, and core-lab imaging at 48 hours showed occlusion clearance in segmental branches anatomically remote from the device — plus a 22.3% mean reduction in right ventricle-to-left ventricle (RV/LV) ratio (P=0.0001).

No patient required an ICU upgrade after the procedure.*

It’s a compelling early look at what an on-the-table protocol can do.

Learn more at thrombolex.com

*Citation on file with THROMBOLEX.

10/13/2026

Three studies. One consistent evidence base.

At VIVA this week, we're walking physicians through the full THROMBOLEX® data set — RESCUE, RESCUE-II, and the RAPID-PE interim analysis — spanning 268 patients and every level of the pulmonary arterial tree, from main to segmental.*

Swipe through for the highlights, or dig into the full data at our booth.

*Citation on file with THROMBOLEX.

10/08/2026

The PERT Consortium 2026, VIVA, and The VEINS meetings are officially in the books.

The THROMBOLEX® team spent the past two weeks talking through Mechanically Channeled Thrombolysis with the physicians managing pulmonary embolism, venous thrombus, and peripheral vascular embolism every day.

Swipe through for a look back at these meetings.

Thank you to everyone who stopped by the booth, sat in on the symposium, or caught the podium session.

10/06/2026

Dr. Wissam Jaber presented late-breaking clinical trial results from the RAPID-PE Study — our prospective, multicenter study of on-the-table Mechanically Channeled Thrombolysis for acute intermediate-risk pulmonary embolism (PE).

In the pre-specified interim analysis of the first 150 of 350 planned patients, the procedure was successful in 100% of cases across 45 operators, with no device-related deaths, no intracranial hemorrhages, and no device-related major adverse events reported.*

Read the full press release here: https://www.prnewswire.com/news-releases/late-breaking-clinical-trial-results-announced-at-the-veins-2026-302897814.html

*Data on file with THROMBOLEX.

10/01/2026

New data from the RAPID-PE Study is being presented during the late-breaking clinical trials session: “A Prospective Multicenter Trial of On-The-Table Mechanically Channeled Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism. Results of the Interim Analysis of 150 Participants in the RAPID-PE Study".

Wissam Jaber, MD will be presenting the interim analysis on podium at The VEINS meeting on Saturday, October 3 at 12:00pm, followed by a panel discussion and Q&A.

This builds on RAPID-PE's earlier interim results, presented at TCT 2025, where the first 50 of 350 planned patients achieved 100% procedural success and zero device-related deaths or hemodynamic decompensation at 7 days.* We're looking forward to sharing the next chapter of this dataset.

Make sure you catch this impactful presentation at The VEINS!

*Data on file.

Address

75 Britain Drive
New Britain, PA
18901

Telephone

+18447926300

Website

http://www.thrombolex.com/

Alerts

Be the first to know and let us send you an email when Thrombolex Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.